ライフサイエンスコーパス: acetylcholine receptor

1 gate the association of the alpha5 nicotinic acetylcholine receptor.

2 t activity of NS6740 at the alpha7 nicotinic acetylcholine receptor.

3 elicit protean agonism at the muscarinic M2 acetylcholine receptor.

4 uscular junction proteins, in particular the acetylcholine receptor.

5 to target the human alpha9alpha10 nicotinic acetylcholine receptor.

6 lic analogue and the alpha9alpha10 nicotinic acetylcholine receptor.

7 ction is mediated by TRPA1 and not nicotinic acetylcholine receptors.

8 ty and was attenuated by blocking muscarinic acetylcholine receptors.

9 where it regulates the function of nicotinic acetylcholine receptors.

10 of the peptide and involved alpha7 nicotinic acetylcholine receptors.

11 eting the cannabinoid 1 and alpha7 nicotinic acetylcholine receptors.

12 an be rescued by an antagonist of muscarinic acetylcholine receptors.

13 mine neuron axons by activation of nicotinic acetylcholine receptors.

14 tein-coupled receptors, including muscarinic acetylcholine receptors.

15 line acting on both nicotinic and muscarinic acetylcholine receptors.

16 responses that result from poorly clustered acetylcholine receptors.

17 uld be attributed to inhibition of nicotinic acetylcholine receptors.

18 y activation of beta(2)-containing nicotinic acetylcholine receptors.

19 ncing myelination by deleting the muscarinic acetylcholine receptor 1 in oligodendrocyte precursor ce

20 gand-gated ion channel the Torpedo nicotinic acetylcholine receptor(10,11), the large body of structu

21 hat the Chrm4 transcript encoding muscarinic acetylcholine receptor 4 (M4) is excessively translated,

22 We and others have investigated muscarinic acetylcholine receptor 4 (M4) positive allosteric modula

23 The nicotinic acetylcholine receptor, a pentameric ligand-gated ion ch

24 target postsynaptic proteins, primarily the acetylcholine receptor (AChR) and inhibit signaling at t

25 at the neuromuscular junction, primarily the acetylcholine receptor (AChR) and the muscle-specific ki

26 cle mutation caused progressive denervation, acetylcholine receptor (AChR) cluster fragmentation, and

27 protein at synapse), which is essential for acetylcholine receptor (AChR) clustering and NMJ (neurom

28 the level of rapsyn, a protein necessary for acetylcholine receptor (AChR) clustering; and expression

29 t MT disorganization and reduces the size of acetylcholine receptor (AChR) clusters.

30 Direct inhibition of acetylcholine receptor (AChR) function by autoantibodies

31 associated with transformation of the muscle acetylcholine receptor (AChR) into an inhibitory channel

32 The maintenance of a high density of the acetylcholine receptor (AChR) is the hallmark of the neu

33 xamined expression of genes involved in anti-acetylcholine receptor (AChR) response in MG, MHC class

34 rs, many involving the muscle-type nicotinic acetylcholine receptor (AChR), although there are aspect

35 une disease caused by antibodies against the acetylcholine receptor (AChR), muscle-specific kinase (M

36 he outer leaflet of the plasma membrane, and acetylcholine receptor (AChR), which is a well-character

37 tin, a two-pass transmembrane protein, as an acetylcholine receptor (AChR)-associated protein, and we

38 er they produce autoantibodies targeting the acetylcholine receptor (AChR-MG) or muscle specific kina

39 Previously it was shown that acetylcholine receptors (AChR) are concentrated in the e

40 ween motoneurons and skeletal muscles, where acetylcholine receptors (AChRs) are concentrated to cont

41 d protein, is required for the clustering of acetylcholine receptors (AChRs) at synaptic sites betwee

42 We used mutations to construct endplate acetylcholine receptors (AChRs) having only one function

43 ing the timing of expression of postsynaptic acetylcholine receptors (AChRs) impacts presynaptic rele

44 for the proper distribution of extrasynaptic acetylcholine receptors (AChRs) in Caenorhabditis elegan

45 BLA principal neurons through activation of acetylcholine receptors (AChRs), (2) enhances glutamater

46 umulation of the neurotransmitter receptors, acetylcholine receptors (AChRs), to the postsynaptic mem

47 mechanism that regulates the distribution of acetylcholine receptors (AChRs).

48 w that endogenous Galphaq-coupled muscarinic acetylcholine receptors activate PKA.

49 The currents of alpha7 nicotinic acetylcholine receptors activated by acetylcholine (ACh)

50 cologic blockade of M-current and muscarinic acetylcholine receptor activation.

51 ed for alpha4beta2 and alpha3beta4 nicotinic acetylcholine receptor affinity and activity.

52 derivatives of the highly potent muscarinic acetylcholine receptor agonist iperoxo.

53 ipts of several targets, including nicotinic acetylcholine receptor alpha 1 and alpha 2 subunit, the

54 Specific nicotinic acetylcholine receptors, alpha3, alpha7, beta2, beta4 we

55 and beta4-subunit-containing human nicotinic acetylcholine receptors (alpha3beta4*-nAChRs).

56 Two alpha4beta2 nicotinic acetylcholine receptor (alpha4beta2-nAChR) isoforms exis

57 osteric modulators (PAM) of alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) is described.

58 ccumulation in BMEC through Alpha7 nicotinic acetylcholine receptor (alpha7 nAChR).

59 compound 28, a novel PAM of alpha7 nicotinic acetylcholine receptor (alpha7 nAChR).

60 a hypothesized role for the alpha7-nicotinic acetylcholine receptor (alpha7-nAChR) in the pathophysio

61 ormal and cancer cells, the alpha7 nicotinic acetylcholine receptor (alpha7-nAChR), was more highly e

62 ypothesized that agonism on alpha7 nicotinic acetylcholine receptor (alpha7nAChR) in fetal microglia

63 ed chronic inflammation via alpha7 nicotinic acetylcholine receptor (alpha7nAChR) signaling. However,

64 show that ILC2s express the alpha7-nicotinic acetylcholine receptor (alpha7nAChR), which is thought t

65 linergic fibers through the alpha7-nicotinic acetylcholine receptor (alpha7nAChR), whose activation d

66 tor of the antiinflammatory alpha7 nicotinic acetylcholine receptor (alpha7nAChR/CHRNA7) that is also

67 lted from local blockade of alpha7-nicotinic acetylcholine receptors (alpha7nAChR).

68 ation of neural signals and alpha7 nicotinic acetylcholine receptors (alpha7nAChRs) on splenic macrop

69 s, RV inflammation, and RV alpha-7 nicotinic acetylcholine receptor and muscarinic acetylcholine type

70 These effects require alpha7 nicotinic acetylcholine receptors and are mediated through the nit

71 ers displayed increased distinct clusters of acetylcholine receptors and axon terminals exhibited num

72 Mediated by nicotinic acetylcholine receptors and choline transporters, such n

73 the epithalamus, densely expresses nicotinic acetylcholine receptors and is critical for nicotine int

74 Using alpha4beta2 nicotinic acetylcholine receptors and the alpha4beta2-selective po

75 Expression of nicotinic (alpha-7 nicotinic acetylcholine receptor) and muscarinic (muscarinic acety

76 n oligodendrocyte glycoprotein, aquaporin 4, acetylcholine receptor, and muscle-specific kinase) was

77 site is the alpha6 subunit of the nicotinic acetylcholine receptors, and different mutations in this

78 hroidine (DHbetaE), the most potent nicotine acetylcholine receptor antagonist (nAChR) of the Erythri

79 Scopolamine (hyoscine) is a muscarinic acetylcholine receptor antagonist that has traditionally

80 that scopolamine, a nonselective muscarinic acetylcholine receptor antagonist, produces rapid antide

81 ropilin-1 antibodies as well as by nicotinic acetylcholine receptor antagonists, suggesting that thes

82 -up was unremarkable except for detection of acetylcholine receptor antibodies in the serum (21.30 nm

83 of 24 OMG patients who were seropositive for acetylcholine receptor antibody (AchR Ab) converted to G

84 a gravis of less than 5 years' duration, had acetylcholine receptor antibody titres of 1.00 nmol/L or

85 eaningful improvements in patients with anti-acetylcholine receptor antibody-positive refractory gene

86 ) and elevated circulating concentrations of acetylcholine-receptor antibody.

87 Acetylcholine receptors are aggregated in the central re

88 Muscarinic acetylcholine receptors are G protein-coupled receptors

89 Muscarinic acetylcholine receptors are G-protein-coupled metabotrop

90 Muscarinic M1-M5 acetylcholine receptors are G-protein-coupled receptors

91 M1 muscarinic acetylcholine receptors are highly expressed in key area

92 Nicotinic acetylcholine receptors are ligand-gated ion channels th

93 Nicotinic acetylcholine receptors are pentameric ion channels that

94 defects, including increased synaptic area, acetylcholine receptor area and density, and extent of p

95 us receptor activity using the muscarinic M2 acetylcholine receptor as a model.

96 cur within seconds of blocking or unblocking acetylcholine receptors at the mouse neuromuscular junct

97 of response to rituximab in the treatment of acetylcholine receptor autoantibody-positive (AChR+) gen

98 iR-1010 or its binding site in the nicotinic acetylcholine receptor beta2 (nAcRbeta2) 3'UTR fail to g

99 ibrations in the presence and absence of the acetylcholine receptor blockers d-tubocurarine and alpha

100 e was due to autoimmunity against muscarinic acetylcholine receptors, blocking their activation.

101 steric modulators (PAMs) of alpha7 nicotinic acetylcholine receptor can increase channel activation b

102 Nicotinic acetylcholine receptors can be assembled from either hom

103 gand-gated channels and how mutations in the acetylcholine receptor cause congenital myasthenic syndr

104 Thus, autoantibodies against M(3) acetylcholine receptors cause acute postganglionic choli

105 ination/retraction, vesicle accumulation and acetylcholine receptor clustering and acetylcholinestera

106 ears independent of the Agrin-LRP4-MuSK-DOK7 acetylcholine receptor clustering pathway.

107 ing organ of vertebrate species, a nicotinic acetylcholine receptor composed only of alpha9 subunits

108 Acetylcholine receptors comprising alpha4 and beta2 subu

109 yramidal cells express specialized nicotinic acetylcholine receptors containing the alpha5 subunit en

110 This work suggests that overstimulation of acetylcholine receptors could disrupt neuronal processin

111 Patients with acetylcholine receptor deficiency can also benefit from

112 Acetylcholine receptor deficiency is the most common for

113 ergic agonists for a cohort of patients with acetylcholine receptor deficiency on anticholinesterase

114 Most patients with acetylcholine receptor deficiency respond well to acetyl

115 d a disease model to mirror the treatment of acetylcholine receptor deficiency, and demonstrate impro

116 can be explained in an experimental model of acetylcholine receptor deficiency, the most common form

117 SS), or secondhand smoke, promoted nicotinic acetylcholine receptor-dependent exacerbation of AA and

118 The alpha7 nicotinic acetylcholine receptor, encoded by the CHRNA7 gene, has

119 Lypd6, an endogenous modulator of nicotinic acetylcholine receptors, enhances experience-dependent p

120 Studies of the mutant acetylcholine receptor expressed in HEK 293 cells reveal

121 ntiinflammatory effects via alpha7 nicotinic acetylcholine receptor-expressing splenic macrophages.

122 sely arranged myosin heavy chain and reduced acetylcholine receptor expression per immunocytochemical

123 onsmokers following stimulation of nicotinic acetylcholine receptors (familywise error-corrected P <

124 myoblast differentiation and aggregation of acetylcholine receptors for the establishment of neuromu

125 bind to the binding pocket of the muscarinic acetylcholine receptor formed by transmembrane alpha-hel

126 The lipid dependence of the nicotinic acetylcholine receptor from the Torpedo electric organ h

127 rons receive cholinergic input via nicotinic acetylcholine receptors from the Kenyon cells; knocking

128 at most synaptic sites, induction of "fetal" acetylcholine receptor gamma subunit (AChRgamma), reduct

129 Thus, FUS regulates acetylcholine receptor gene expression in subsynaptic my

130 ociations with sequence variants in nicotine acetylcholine receptor genes and at other loci.

131 ion factor ERM to stimulate transcription of acetylcholine receptor genes.

132 ors (PAMs) of the M(1) subtype of muscarinic acetylcholine receptor have emerged as an exciting new a

133 selective activators of the M(4) muscarinic acetylcholine receptor have potential as a novel treatme

134 Muscarinic acetylcholine receptors have been implicated as potentia

135 its are the most abundant class of nicotinic acetylcholine receptor in the brain.

136 out the physiological function of muscarinic acetylcholine receptors in learning in adult flies.

137 the developmental switch from fetal to adult acetylcholine receptors in muscle (AChRs) and the functi

138 This strongly suggests a role of muscarinic acetylcholine receptors in the generalized sensitization

139 predict alcohol, and suggest that nicotinic acetylcholine receptors in the NAc are critical for this

140 encodes the alpha3 subunit of the nicotinic acetylcholine receptor, in five affected individuals fro

141 h can also activate, potentiate, and inhibit acetylcholine receptors, including neuronal nicotinic re

142 nd nicotine in the two major brain nicotinic acetylcholine receptors interact differently with the py

143 rug scopolamine was used to block muscarinic acetylcholine receptors involved in working memory.

144 ies conducted on the extracellular domain of acetylcholine receptors, ion channels from prokaryote ho

145 The alpha7 nicotinic acetylcholine receptor is a homopentameric ion channel f

146 The muscarinic acetylcholine receptor is an important modulator of medi

147 vely apply our model to the human muscarinic acetylcholine receptor M1, finding four experimentally c

148 teric modulators (PAMs) of the M1 muscarinic acetylcholine receptor (M1 mAChR) are a promising strate

149 or to detect activation of the M1 muscarinic acetylcholine receptor (M1 mAChR) in vitro and in vivo M

150 ne receptors, particularly the M1 muscarinic acetylcholine receptor (M1 mAChR), which was previously

151 itulated with blockade of M1-type muscarinic acetylcholine receptors (M1-AChR); however, the cellular

152 with beta-arrestin binding to M1 muscarinic acetylcholine receptors (M1Rs) in two different binding

153 express somatostatin, VIP, or the muscarinic acetylcholine receptor M2.

154 The M2 muscarinic acetylcholine receptor (M2R) is a prototypical GPCR that

155 The M2 muscarinic acetylcholine receptor (M2R) was found to exhibit depola

156 cini preferentially expressed the muscarinic acetylcholine receptor M3 and maintained physiological r

157 Targeting acetylcholine receptor M3 prevents the progression of ai

158 function regulated through the M3-muscarinic acetylcholine receptor (M3-mAChR).

159 AuAbs to desmocollin 3 (Dsc3), M3 muscarinic acetylcholine receptor (M3AR), and secretory pathway Ca(

160 uction of antinuclear and anti-M3 muscarinic acetylcholine receptor (M3R) autoantibodies and impairme

161 teric modulators (PAMs) of the M1 muscarinic acetylcholine receptor (mAChR) achieve exquisite selecti

162 stibular afferents is mediated by muscarinic acetylcholine receptor (mAChR) activation and the subseq

163 Muscarinic acetylcholine receptor (mAChR) activation in rRPa contri

164 Nanoinjections of the muscarinic acetylcholine receptor (mAChR) agonist, oxotremorine, or

165 ovel 1,4-dioxane analogues of the muscarinic acetylcholine receptor (mAChR) antagonist 2 was synthesi

166 Muscarinic acetylcholine receptor (mAChR) blockade by scopolamine p

167 e allosteric modulators of the M5 muscarinic acetylcholine receptor (mAChR) have been described, but

168 in signaling of the M1 subtype of muscarinic acetylcholine receptor (mAChR) in the prefrontal cortex

169 The M(1) muscarinic acetylcholine receptor (mAChR) plays an important role i

170 M(1) muscarinic acetylcholine receptor (mAChR) positive allosteric modul

171 Selective activation of the M1 muscarinic acetylcholine receptor (mAChR) via a positive allosteric

172 We previously reported a form of muscarinic acetylcholine receptor (mAChR)-dependent long-term depre

173 tic studies further indicate that muscarinic acetylcholine receptor (mAchR)/Galphao signaling produce

174 Muscarinic acetylcholine receptors (mAChR) play important roles in

175 ng in adult flies requires type A muscarinic acetylcholine receptors (mAChR-A), particularly in the g

176 mba snakes that primarily bind to muscarinic acetylcholine receptors (MAChRs) and modulate their func

177 Furthermore, inhibition of muscarinic acetylcholine receptors (mAChRs) reduced calcium activit

178 racterized two types (A and B) of muscarinic acetylcholine receptors (mAChRs), which were expressed i

179 yclic voltammetry with local pharmacological acetylcholine receptor manipulation.

180 We therefore investigated metabotropic acetylcholine receptor-mediated modulation by using isol

181 pecific mechanisms of alpha3beta4*-nicotinic acetylcholine receptor modulation by the prototoxin lynx

182 y labeled dibenzodiazepinone-type muscarinic acetylcholine receptor (MR) antagonists, including dimer

183 Muscarinic acetylcholine receptors (MRs), comprising five subtypes

184 ve processes that are modulated by nicotinic acetylcholine receptor (nAChR) activation by cholinergic

185 ending plasma levels of the alpha7-nicotinic acetylcholine receptor (nAChR) agonist 3-(2,4-dimethoxyb

186 Among them is epibatidine, a nicotinic acetylcholine receptor (nAChR) agonist that is lethal at

187 icotine or ABT-418, an alpha4beta2 nicotinic acetylcholine receptor (nAChR) agonist, normalized MSO t

188 GeXIVA inhibits the alpha9alpha10 nicotinic acetylcholine receptor (nAChR) and is analgesic in anima

189 These effects were blocked by the nicotinic acetylcholine receptor (nAChR) antagonist mecamylamine.

190 ind that SAT1 selectively controls nicotinic acetylcholine receptor (nAChR) biogenesis.

191 pha-conotoxin CIA, a potent muscle nicotinic acetylcholine receptor (nAChR) blocker with a significan

192 a desensitized state of the alpha7 nicotinic acetylcholine receptor (nAChR) have been associated with

193 with this soluble surrogate of the nicotinic acetylcholine receptor (nAChR) in a cooperative fashion,

194 The nicotinic acetylcholine receptor (nAChR) is a major target of auto

195 The alpha7 nicotinic acetylcholine receptor (nAChR) is a potential drug targe

196 The alpha6beta4 nicotinic acetylcholine receptor (nAChR) is enriched in dorsal roo

197 ctivity of the muscle-type Torpedo nicotinic acetylcholine receptor (nAChR) is highly sensitive to li

198 The alpha4beta2 nicotinic acetylcholine receptor (nAChR) is important in central n

199 rovide an improved model to assess nicotinic acetylcholine receptor (nAChR) ligands for treating chro

200 Nicotinic acetylcholine receptor (nAChR) ligands that lack agonist

201 al role in the characterization of nicotinic acetylcholine receptor (nAChR) structure and function an

202 alpha7 (IC(50) 77.1 +/- 0.05 mum) nicotinic acetylcholine receptor (nAChR) subtypes, but the activit

203 interacting with alpha7-containing nicotinic acetylcholine receptor (nAChR) subtypes, leads to subnuc

204 e is known about the role of beta4 nicotinic acetylcholine receptor (nAChR) subunit encoded by this c

205 n CHRNA3, which encodes the alpha3 nicotinic acetylcholine receptor (nAChR) subunit gene, increases r

206 RNA3, the gene encoding the alpha3 nicotinic acetylcholine receptor (nAChR) subunit, increases vulner

207 for the alpha5, alpha3, and beta4 nicotinic acetylcholine receptor (nAChR) subunits, to nicotine add

208 A7, the gene coding for the alpha7 nicotinic acetylcholine receptor (nAChR), and manifest a variable

209 CHRNA7, encoding for the alpha7 nicotinic acetylcholine receptor (nAChR), has been suggested as a

210 (PAMs) acting on the human alpha7 nicotinic acetylcholine receptor (nAChR).

211 appear to be related to the alpha7 nicotinic acetylcholine receptor (nAChR).

212 fferent synapse is a alpha9alpha10 nicotinic acetylcholine receptor (nAChR).

213 beta2* nicotinic acetylcholine receptors (nAChR) are necessary and suffic

214 ulation and synaptic clustering of nicotinic acetylcholine receptors (nAChR) during neurotrophic fact

215 vity of classical agonists for the nicotinic acetylcholine receptors (nAChR) has prompted us to ident

216 sociations between variants in the nicotinic acetylcholine receptors (nAChR) subunits and nicotine de

217 with very high affinity for brain nicotinic acetylcholine receptors (nAChR).

218 ed TGFBR2 and the nicotinic antiinflammatory acetylcholine receptor nAChRa7 as murine and human miR-2

219 ivation of 42 genes, including the nicotinic acetylcholine receptors nAChRalpha1 and nAChRalpha3, in

220 Nicotinic acetylcholine receptors (nAChRs) and gamma-aminobutyric

221 new group of inhibitors for muscle nicotinic acetylcholine receptors (nAChRs) and some neuronal nAChR

222 Nicotinic acetylcholine receptors (nAChRs) are crucial for communi

223 Nicotinic acetylcholine receptors (nAChRs) are members of the Cys-

224 Neuronal nicotinic acetylcholine receptors (nAChRs) are promising drug targ

225 Alpha7 nicotinic acetylcholine receptors (nAChRs) are promising novel tar

226 alpha7 nicotinic acetylcholine receptors (nAChRs) are ubiquitous in the n

227 btx) and prevent its inhibition of nicotinic acetylcholine receptors (nAChRs) as a lead for the devel

228 Nicotinic acetylcholine receptors (nAChRs) assemble in the endopla

229 Nicotinic acetylcholine receptors (nAChRs) belong to the family of

230 Here, we show that activation of nicotinic acetylcholine receptors (nAChRs) by quantal release of a

231 Many peptide ligands of nicotinic acetylcholine receptors (nAChRs) contain a large number

232 ficant cholinergic innervation and nicotinic acetylcholine receptors (nAChRs) contribute greatly to t

233 t widely co-abused substances, and nicotinic acetylcholine receptors (nAChRs) contribute to the behav

234 hances nicotine-induced changes in nicotinic acetylcholine receptors (nAChRs) expressed on midbrain D

235 d shows high binding affinity with nicotinic acetylcholine receptors (nAChRs) expressed on the surfac

236 gically distinguishing alpha3beta2 nicotinic acetylcholine receptors (nAChRs) from closely related su

237 Antagonists of alpha9alpha10 nicotinic acetylcholine receptors (nAChRs) have been proposed as a

238 a suggest a complex interaction of nicotinic acetylcholine receptors (nAChRs) in regulating vestibula

239 The two major nicotinic acetylcholine receptors (nAChRs) in the brain are the al

240 Antagonism of nicotinic acetylcholine receptors (nAChRs) in the medial habenula

241 nduced upregulation of alpha4beta2 nicotinic acetylcholine receptors (nAChRs) is associated with chan

242 Nicotinic acetylcholine receptors (nAChRs) mediate and modulate sy

243 Nicotinic acetylcholine receptors (nAChRs) modulate synaptic activ

244 neurons acting through presynaptic nicotinic acetylcholine receptors (nAChRs) on PFn terminals.

245 KEY POINTS: Neuronal nicotinic acetylcholine receptors (nAChRs) play a fundamental role

246 Blocking beta2 or alpha7 nicotinic acetylcholine receptors (nAChRs) prevents, respectively,

247 but very little is known about how nicotinic acetylcholine receptors (nAChRs) regulate LHb activity.

248 ression and clustering of neuronal nicotinic acetylcholine receptors (nAChRs) remain poorly defined.

249 ping drugs that act at alpha4beta2 nicotinic acetylcholine receptors (nAChRs) to treat alcohol use di

250 t of aging on presynaptic neuronal nicotinic acetylcholine receptors (nAChRs) within the circuitry of

251 the highest density in alpha4beta2 nicotinic acetylcholine receptors (nAChRs) within the whole cortex

252 A d-peptide ligand of the nicotine acetylcholine receptors (nAChRs), termed (D)CDX, enables

253 ear synapse involves alpha9alpha10 nicotinic acetylcholine receptors (nAChRs), which assemble in hair

254 vity for neuronal over muscle-type nicotinic acetylcholine receptors (nAChRs).

255 g GABA(A) receptors (GABA(A)R) and nicotinic acetylcholine receptors (nAChRs).

256 ant-derived alkaloid that binds to nicotinic acetylcholine receptors (nAChRs).

257 actions through a family of brain nicotinic acetylcholine receptors (nAChRs).

258 lpha5beta4-, and alpha7-containing nicotinic acetylcholine receptors (nAChRs).

259 vation of alpha9alpha10-containing nicotinic acetylcholine receptors (nAChRs).

260 We administered a novel alpha7 nicotinic acetylcholine receptor-negative allosteric modulator, BN

261 se results represent the first evidence that acetylcholine receptors negatively modulate muscle spind

262 Up-regulation of nicotinic acetylcholine receptors normalized before day 4 followin

263 dependence and stimulation of the nicotinic acetylcholine receptor on the ability to interpret valen

264 nd acute effects of stimulation of nicotinic acetylcholine receptors on behavioral and neural signatu

265 binding follows hyperbolic (M(4) muscarinic acetylcholine receptors) or nonhyperbolic relationships

266 cally prevented by the alpha4beta2 nicotinic acetylcholine receptor partial agonist and alpha7 recept

267 strategy is to selectively target muscarinic acetylcholine receptors, particularly the M1 muscarinic

268 his to be the case with the alpha7 nicotinic acetylcholine receptor positive allosteric modulator (PA

269 racemic preparation, is an alpha7 nicotinic acetylcholine receptor positive allosteric modulator (PA

270 r in animals through inhibition of nicotinic acetylcholine receptors present in the central nervous s

271 acetylcholine-gated channel and a muscarinic acetylcholine receptor, respectively.

272 on of the ER-resident chaperone of nicotinic acetylcholine receptors, RIC-3, leads to increased muscl

273 f geniculocortical inputs with M2 muscarinic acetylcholine receptor-rich patches in layer 1 (L1) sugg

274 ternal risk alleles for the alpha5 nicotinic acetylcholine receptor (rs16969968).

275 a presynaptic inhibition of alpha7-nicotinic acetylcholine receptor signaling.

276 treatment reduced disease severity, lowered acetylcholine receptor-specific Abs, and decreased CD19(

277 Correspondingly, model mice had fewer acetylcholine receptor-stained NMJs detected by fluoresc

278 igra pars reticulata (SNr) act on muscarinic acetylcholine receptor subtype 4 (M4) to oppose cAMP-dep

279 ith targeted disruption of single muscarinic acetylcholine receptor subtype genes (M(1) to M(5)) and

280 iotracer (11)C-LSN3172176 for the muscarinic acetylcholine receptor subtype M1.

281 in (MyoG), Hdac4, Ampd3, Trim63 (MuRF1), and acetylcholine receptor subunit alpha1 (Chrna1).

282 egulatory pathway mediated via the nicotinic acetylcholine receptor subunit CHRNA2.

283 anges in alpha4, alpha3, and beta2 nicotinic acetylcholine receptor subunit mRNA levels in the nucleu

284 Notably, we only observed epsilon acetylcholine receptor subunit protein upregulation and

285 species from all five subtypes of muscarinic acetylcholine receptors, suggesting allosteric binding.

286 h ion channels of the ligand-gated nicotinic acetylcholine receptor superfamily (namely alpha-amino-3

287 tor ligand to activate a modified muscarinic acetylcholine receptor that is insensitive to acetylchol

288 ract may primarily target muscarinic subtype acetylcholine receptors that regulate memory processes.

289 losteric modulator (PAM) of alpha7 nicotinic acetylcholine receptors that, like 4BP-TQS and its activ

290 ryoEM structure of sAB bound human nicotinic acetylcholine receptor, this work demonstrates that thes

291 We assessed the contribution of muscarinic acetylcholine receptors to motivated behaviour in mice,

292 econdary Gi/o coupling, using the muscarinic acetylcholine receptor type 2 (M2R) as the primary Gi/o-

293 by CRF results in the activation muscarinic acetylcholine receptors type 5, which mediate potentiati

294 In PAH RV samples, alpha-7 nicotinic acetylcholine receptor was increased and acetylcholinest

295 -inflammatory alpha7-nAChR (alpha7-nicotinic acetylcholine receptor) was similar in young SHR and WKY

296 The corresponding postsynaptic acetylcholine receptors were stained using Alexa Fluro-5

297 vitro demonstrated that the mutant nicotinic acetylcholine receptors were unable to generate current

298 probe the ion channel pore of the nicotinic acetylcholine receptor, which is a prototypical Cys-loop

299 with nonselective antagonists of muscarinic acetylcholine receptors, which have many undesirable sid

300 ll types expressing alpha8 subunit nicotinic acetylcholine receptor, while SPO and cOv are characteri